Animal Model Market size to exceed $30.6bn by 2028

Animal Model Market size is set to exceed USD 30.6 billion by 2028, according to a new research report by Global Market Insights Inc.
 

Surging prevalence of infectious and chronic diseases is anticipated to drive the market growth globally. As per the World Health Organization, in 2018, around 13% of cancer cases diagnosed were attributed to carcinogenic infections globally. Additionally, the severe health concerns associated with chronic ailments are anticipated to stimulate the demand for research studies, thereby leading to the significant adoption of animal model in pharmaceutical companies, government research organizations, etc.
 

The demand for CRISPR technology has augmented in the past few years as it facilitates precise and efficient genetic modification of different eukaryotic genomes. Numerous academic & research institutes and biotech firms are also working toward the development of new medical and other non-conventional applications of CRISPR technology.
 

Physiological similarities in humans and animals are expected to drive the market revenue

Physiological similarities between humans and animals are anticipated to fuel the animal model market revenue in the coming years. These animals have a shorter life span; however, they have a high physiological resemblance to humans. This is increasingly augmenting the applications of animal model in biomedical research to develop new treatment methods for numerous infectious and chronic diseases. The physiological similarity means that around 90% of the veterinary drugs that are used to treat animals are the same as, or very similar to, those used to treat human diseases. As per the research studies, the human genotype is 99% homogeneous to genotype in mice, comprising 85% of resemblance in protein-coding spaces between human and mice genomes.
 

Surge in the application of rat models to study several complex disorders are anticipated to stimulate the market statistics

Based on animal type, animal model market is segmented into mice, rats, fish, birds, cattle, pigs, amphibian, guinea pigs, dogs, rabbits, monkeys, sheep, hamsters, and others. The rats segment exceeded USD 1,394 million in 2021. This is attributable to the growing demand for transgenic rat models in chronic diseases research, the physiological similarity between rat & human genotype, and optimum outcomes delivered in investigational studies among others. Rat models are considered as highly suitable and preferred ideal models attributed to several variables comprising short generation time, known genetic background & microbial status, and similarities to human disease conditions among others. Research studies found that around one-fourth of the human genome is shared with rats. Such physiological similarities between rats and humans would upsurge the demand and adoption of rat model-based research, thereby augmenting the industry landscape.
 

Browse key industry insights spread across 590 pages with 902 market data tables & 18 figures & charts from the report, “Animal Model Market Forecasts By Animal Type (Mice, Rats, Fish, Birds, Cattles, Pigs, Amphibians, Guinea Pigs, Dogs, Cats, Rabbits, Monkeys, Sheep, Hamsters), By Technology (CRISPR, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer), Applications (Research & Development {Infectious Disease, Immunological Diseases, Cancer, Cardiovascular Diseases, Diabetes, Genetic Diseases, Neurological Diseases, Obesity, NAFLD/NASH, Renal disease, Diabetic eye disease, Fibrosis, Microbiome}, Production and Quality Control, Academics, Preclinical Applications {Infectious Disease, Immunological Diseases, Cancer, Cardiovascular Diseases, Diabetes, Genetic Diseases, Neurological Diseases, Obesity, NAFLD/NASH, Renal disease, Diabetic eye disease, Fibrosis, Microbiome}), Use (Human and Veterinary), End-use, (Companies {Pharmaceutical, Biotechnology, Cosmetics, Organizations {Government, Non-government}, Academic and Research Institutes, Contract Research Organizations (CRO)), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2022 – 2028”in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/animal-model-market
 

Growing adoption of microinjection technology in transgenic research models will propel the market trends

Based on technology, animal model market is segmented into microinjection, CRISPR, embryonic stem cell injection, nuclear transfer, and others. The microinjection segment is anticipated to expand at a CAGR of 7.9% from 2022 to 2028. The adoption of microinjection technology in transgenic research model generation is surging across the globe attributed to its applicability to a wide variety of species, increases the embryo survival chances, facilitates injecting microliters of cell's fluid into other recipient tissues, etc. These techniques are independent that proved to be effective in mammals and preferably utilized to investigate the gene expression using mice research models.
 

The animals produced through microinjection technology are playing a vital role in research concerned with numerous therapeutic areas including cancer, diabetes, and cardiovascular research among others. These approaches are considered comparatively reliable and find applications in different research models. These factors have augmented the adoption and demand for utilizing microinjection techniques that will significantly impel the market outlook.
 

Several advantages delivered by animal model in production and quality control is expected to fuel the industry expansion

Based on application, animal model market is segmented into research and development, production and quality control, academics, preclinical applications, and others. The production and quality control segment were valued at more than USD 2,684 million in 2021 and is anticipated to witness significant growth in the coming years. The growing adoption of animal model-based research to improve the efficacy of production and quality control is increasing significantly. For instance, the cerebrospinal fluid (CSF) biomarkers can be used to understand pharmacology relationships in clinical trials. To enable the use of these biomarkers in humans, investigations in preclinical species comprising mice, rats, and nonhuman primates are significant.
 

An upsurge in cases of infectious diseases comprising hepatitis and COVID-19 is augmenting the demand for animal model in production and quality control areas to test the safety & efficacy of the medication. As per the research studies, around 15% of the total research models are used at different evaluation stages of vaccine production and quality control. Moreover, the growing demand for targeted therapy and personalized medicine to treat cancer patients has contributed to the stringent production and quality control check. Thus, the variables are projected to significantly foster business landscape.
 

Increasing prevalence of zoonotic diseases along with favorable government initiatives will spur the industry statistics

Based on use, the animal model market is segmented into human and veterinary. The veterinary segment is anticipated to expand at 7.8% CAGR from 2022 to 2028. The increasing prevalence of various fatal animal disorders is contributing to the growing research activities related to veterinary medicines. Rising pet adoption coupled with increasing disposable income spent significantly on pet care is stimulating the adoption and demand for novel veterinary medications. The rising incidence of zoonotic disorders across the globe is also contributing to the market expansion.
 

According to the NCBI, around 60% of known infectious ailments and over 75% of emerging infectious ailments are zoonotic in origin. These factors have increased the demand for animal model-based research studies to develop effective treatments or drugs to improve animal health. Moreover, various funding programs by government organizations to boost the R&D activities for advancing the research on the diagnosis & treatment of various animal diseases will favor overall industry trends.
 

Increasing adoption of animal model by academic & research institutes is projected to boost the market outlook

Based on end-use, the market is segmented into companies, organizations, academic & research institutes, and contract research organizations (CRO). The academic and research institutes segment exceeded USD 346 million in 2021. This growth is attributed to the rising adoption of animal model in academic and research institutes, growing research volume, etc. Several market players are emphasizing to introduce novel transgenic research models to study and understand the behavior of drug toxicity in research institutes. Owing to numerous clinical advantages offered by the animal model in the long run, the segment is set to spur market growth in the coming years. As per the Survey of Research and Development Expenditures at Universities and Colleges, academic institutes account for around 13% of total R&D activities costs in the U.S. As a result, the increasing research activities along with the adoption of research model at academic and research institutes is anticipated to fuel the overall market demand.
 

High number of ongoing R&D projects and access to advanced technologies in the Europe region is projected to propel the regional business scenario

Germany animal model market exceeded USD 427 million in 2021. This market share is owing to the increasing usage of animal model-based research, surging consumption of personalized medication, etc. In Germany, animal model is an important part of academics & research institutes as they are widely used for conducting experiments, education purposes, etc. These models also play a crucial role in infectious diseases and are highly used by biopharmaceutical companies in the country to test the toxicity of medications.
 

Moreover, transgenic humanized mice models were produced at a rapid pace in Germany to understand the expression of human ACE2 and SARS-CoV-2 genes owing to the rising cases of coronavirus infection. Thus, the above-mentioned factors are anticipated to amplify the regional business expansion.
 

Key players are adopting several business strategies to capture significant market share

Some of the major players operational in the animal model industry are Charles River, The Jackson Laboratory, Janvier Labs, Harbour BioMed, and genOway among others. Increasing focus of the market players on manufacturing and developing innovative products for effective treatment of diseases will provide significant growth opportunities.
 

These players are proposing strategic acquisitions, mergers, collaborations, and partnerships to launch new research model and strengthen their industrial position. For instance, In January 2020, genOway announced a strategic alliance with Merck to strengthen CRISPR/Cas9 and commercialize the generation & application of all other animal cell models to support its consumer’s internal research. This strategic move assisted the company in expanding its research model portfolio.